Learn from Dr. Robert Rowen MD. how his Ozone journey started and how easy he was convinced when he saw results over 31 years ago.
95% Of Us Have Epstein-Barr Virus (EBV), What Can We DO?
Epstein-Barr Virus (EBV) is spread through intimate contact – meaning bodily fluids, primarily saliva, as well as blood and semen. Hence the commonly called kissing disease. Regardless if the Epstein-Barr Virus (EBV) is active or dormant, it can still be spread to others thus resulting in its high prevalence.
Consequentially, as it is spread through bodily fluids additional to kissing and sex, it can be spread by sharing drinks or drinking from the same glass, sharing a toothbrush, organ transplant or blood transfusions.
Epstein-Barr Virus (EBV) is a member of the herpes family and as previously mentioned the infection can often be symptom free.
When our system is attacked by a viral infection, our bodies respond by commanding our B cells within our immune system to crank out antibodies and battle the invaders. However, when an EBV infection occurs, something unusual happens. The Epstein-Barr Virus (EBV) invades the B cells themselves and takes over the control of their functions. Circulating B cells spread the infection throughout the entire system particularly the liver, spleen and peripheral lymph nodes.
The herpes viridae family include: herpes simplex viruses 1 and 2 (HSV-1 and HSV-2), varicella-zoster virus, Epstein-Barr virus (EBV or HHV-4), cytomegalovirus (HHV-5) among several others.
A characteristic of the herpes viridae family is that once you’ve have it, the virus no longer leaves the host after the first infection and nests in a cell type of the organism causing a so-called latent infection. This occurs in a variable time depending on the type of virus and the sensitivity of the host. From this latency state of the Epstein-Barr Virus (EBV) can reactivate, even after many years, resulting in a recurrence of the disease.
Epstein-Barr Virus (EBV), also known as the human herpesvirus 4, is one of the eight viruses in the herpes family and the most common virus present in humans. It is best known as the cause of infectious mononucleosis (glandular fever) which is often referred to as ‘the kissing disease’. It is estimated that most people, roughly 90-95% of the world’s population have been infected with Epstein-Barr Virus (EBV) at some point in their lives.
Fortunately, for most of people the virus stays dormant and doesn’t present with any noticeable symptoms however this does not mean the body isn’t impacted by the infection. Furthermore, in some individuals the Epstein-Barr Virus (EBV) infection can reactivate resulting in the serious dreaded symptoms/conditions such as chronic fatigue syndrome (CFS), autoimmune disease, fever, enlarged spleen and so on.
The stimuli that induce the re-activation of Epstein-Barr Virus (EBV) viral activity can be temperature changes, trauma, stress and especially changes in the immune defense status of the body such as immunodeficiency. For a small amount of people, the Epstein-Barr Virus (EBV) can actually remain chronically active known as chronic active Epstein Barr virus (CAEBV).
Epstein-Barr Virus (EBV) is responsible for productive lytic infections, which after a period of time depending on the reactivity of the infected person, turns into a latent infection. The latency site is different for each herpes virus, but they reside in areas of the body that are protected from constant attack of the immune system, which makes the eradication of these viruses such as Epstein-Barr Virus (EBV) from the infected person extremely difficult.
Furthermore, research has shown that Epstein-Barr Virus (EBV) does not simply cause glandular fever (infectious mononucleosis) but several other serious diseases. It was discovered that a protein produced by the Epstein-Barr Virus (EBV) interacts with a number of genes – associated with these diseases. Through these gene mutations the function of the immune system is altered, speculated to primarily affect B cells which produce the antibodies in response to infection and viruses.
Diseases found to be linked with Epstein-Barr Virus (EBV) include;
Additionally, Epstein-Barr Virus (EBV) is estimated to cause over 200,000 cases of cancer worldwide, principally lymphomas (Burkitt’s lymphoma, Hodgkin’s lymphoma), nasopharyngeal cancer and some stomach cancers.
Common symptoms of latent and active Epstein-Barr virus include:
Fatigue, sometimes severe and often the most common symptom (chronic fatigue syndrome). Chronic fatigue syndrome has various different names such as: epidemic neuromyasthenia, myalgic encephalomyelitis, postviral fatigue syndrome, chronic fatigue and immune system dysfunction syndrome.
Lack of appetite
Sore throat and swollen glands
Swollen or enlarged liver or spleen
Flu-like symptoms, in children: diarrhea or ear infections
Due to how ubiquitous Epstein-Barr Virus (EBV) infection is and the fact that there is no specific and effective treatment available, it is often ignored by the medical industry, or at least its impact on health for many people has been grossly underestimated.
There is no permanent cure for Epstein-Barr Virus (EBV), and therefore treatments should rather focus on returning the body to homeostasis by reducing the EBV infection and in turn shutting down the viral activity.
Ozone plays a fundamental role in the treatment of multifactorial infectious disease states such as Epstein-Barr Virus (EBV) infection or chronic fatigue associated with EBV; this is due to its direct and indirect mechanism of action:
To treat Epstein-Barr Virus (EBV) infection ozone is administered through various different routes and with variable therapeutic doses of ozone. It is administered in the form of gas. Ozone represents an unstable molecule characterized by 3 atoms of oxygen. Ozone gas comes in contact with fluid within the body (mainly water) or organic matter (cells, bacteria, viruses, stool, blood…) and prompt Ozonolysis takes place. This process happens in fractions of secondsand the reaction leads to the formation of: Ozonides aldehydes and Peroxides hydrogen peroxide (H2O2).
Ozonides aldehydes and hydrogen peroxide (H2O2) induce a mild oxidative stress at cellular level. H2O2 is quickly reduced to H2O (water) and O2 (oxygen) by free anti-oxidants in the blood and cells. The half-life of H2O2 is literally 60 seconds and yet its intracellular concentration is critical in order to activate the biochemical pathways. Thus it causes an oxidative reaction, which transforms into second messengers with long lasting action. No damage to healthy cells occurs during this process.
Ozone and Ozonites destroy viruses by diffusing through the protein coat into the nucleic acid core, resulting in damage of the viral RNA. Unlike healthy cells, which posses’ complex enzyme systems (superoxide dismutase, catalase, peroxidase) viruses have no protections against oxidative stress, therefore making viruses such as Epstein-Barr Virus (EBV) vulnerable to ozone.
The case report discussed two patients, one young boy diagnosed with acute meningoencephalitis, as well as positive serology results for cytomegalovirus (CMV) and Epstein Barr Virus. After intravenous antibiotic and antiviral therapy for the meningoencephalitis the patient was diagnosed with post-infectious CFS (due to the positive Epstein-Barr Virus (EBV) infection). The patient was then treated with ozonetherapy, rectal insufflation at twice weekly for 4 weeks continued to weekly treatments for a further 4 weeks; this was accompanied with nutritional/herbal supplementation. The patient went into complete remission of symptoms associated with chronic fatigue and Epstein-Barr Virus.
The second patient they treated was a world champion athlete for post-infectious CFS with a similar clinical picture of previous toxoplasmosis infection and asymptomatic assessed mononucleosis (EBV). The patient was also treated with rectal ozone therapy and they observed a complete remission of the CFS neurological and functional symptoms of post infection. The ozone therapy was performed throughout the patients ongoing training until remission was completed. One year later the athlete went on to win a gold medal in the World Champion title.
In this 2019 case report it was concluded that ozone therapy is the only effective therapeutic treatment to restore and alleviate the symptoms from post infectious meningoencephalitis syndromes, chronic fatigue from both infectious (Epstein-Barr Virus (EBV)) and non-infectious disease states.
Reducing the Epstein-Barr Virus (EBV) infection with regular rectal and vaginal ozone treatments is the first and most important treatment. This includes hygiene with ozone water and ozone oils for topical application.
Once this has been implemented the next step is restoring the body’s immune system. Being immunocompromised is a major risk factor for reactivating EBV infection.
How do we ensure our immune system is functioning properly?
Bocci, V. (n.d.). Ozonization of Blood for the Therapy of Viral Diseases and Immunodeficiencies . A Hypothesis, 30–34.
Bocci, V. (1996). Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today. Journal of Biological Regulators and Homeostatic Agents.
Burleson, G. R., Murray, T. M., Burleson, G. R., Murray, T. M., & Pollard, M. (1975). Inactivation of Viruses and Bacteria by Ozone , With and Without Sonication Inactivation of Viruses and Bacteria by Ozone , With and Without Sonication.
Carpendale, M. T. F., & Frceberg, J. K. (1991). Ozone inactivates H IV at noncytotoxic concentrations, 16, 281–292.
Clavo, B., Pérez, J. L., López, L., Suárez, G., Lloret, M., Rodríguez, V., … Robaina, F. (2004). Ozone Therapy for Tumor Oxygenation: a Pilot Study. Evidence-Based Complementary and Alternative Medicine, 1(1), 93–98. httpss://doi.org/10.1093/ecam/neh009
Cohen, J. I. (2009). Optimal treatment for chronic active Epstein-Barr virus disease: Editorial. Pediatric Transplantation, 13(4), 393–396. httpss://doi.org/10.1111/j.1399-3046.2008.01095.x
Elvis, A. M., & Ekta, J. S. (2011). Ozone therapy : A clinical review,2(1), 66–70. httpss://doi.org/10.4103/0976-9668.82319
Harley, J. B., Chen, X., Pujato, M., Miller, D., Maddox, A., Forney, C., … Weirauch, M. T. (2018). Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nature Genetics, 50(5), 699–707. httpss://doi.org/10.1038/s41588-018-0102-3
Hess, R. D. (2004). Routine Epstein-Barr virus diagnostics from the laboratory perspective: Still challenging after 35 years. Journal of Clinical Microbiology, 42(8), 3381–3387. httpss://doi.org/10.1128/JCM.42.8.3381-3387.2004
Landais, E., Saulquin, X., & Houssaint, E. (2005). The human T cell immune response to Epstein-Barr virus. International Journal of Developmental Biology, 49(2–3 SPEC. ISS.), 285–292. httpss://doi.org/10.1387/ijdb.041947el
Martínez-Sánchez, G., Delgado-Roche, L., Díaz-Batista, A., Pérez-Davison, G., & Re, L. (2012). Effects of ozone therapy on haemostatic and oxidative stress index in coronary artery disease. European Journal of Pharmacology,691(1–3), 156–162. httpss://doi.org/10.1016/j.ejphar.2012.07.010
Mawsouf, M. N., Tanbouli, T. T., Mawsouf, M. N., & Tanbouli, T. T. (2016). Ozone : Science & Engineering The Journal of the International Ozone Association OzoneTherapy in Patients with Viral Hepatitis C : Ten Years ’ Experience Ozone Therapy in Patients with Viral Hepatitis C : Ten Years ’ Experience, 9512(June). httpss://doi.org/10.1080/01919512.2012.720161
Miyamura, T., Chayama, K., Wada, T., Yamaguchi, K., Yamashita, N., Ishida, T., … Morishima, T. (2008). Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation. Pediatric Transplantation, 12(5), 588–592. httpss://doi.org/10.1111/j.1399-3046.2007.00873.x
Morelli, L., Bramani, S. C., & Morelli, F. C. (2019). Oxygen-ozone therapy in meningoencephalitis and chronic fatigue syndrome. Treatment in the field of competitive sports: case report. Ozone Therapy, 4(1). httpss://doi.org/10.4081/ozone.2019.8176
Ms, J. D., Menéndez-cepero, S., Macías-abraham, C., & Ms, L. F. (2017). Systemic OzoneTherapy by Rectal Insufflation for Immunoglobulin A Deficiency, 29–35.
Nogales, C. G., Ferrari, P. H., Kantorovich, E. O., & Lage-Marques, J. (2008). Ozonetherapy in medicine and dentistry. Journal of Contemporary Dental Practice, 9(4), 1–9.
Ozler, M., Akay, C., Oter, S., Ay, H., & Korkmaz, A. (2016). Similarities and differences of hyperbaric oxygen and medical ozone applications, 5762(June). httpss://doi.org/10.3109/10715762.2011.627331
Pender, M. P. (2012). CD8+ t-cell deficiency, epstein-barr virus infection, vitamin d deficiency, and steps to autoimmunity: A unifying hypothesis. Autoimmune Diseases, 1(1). httpss://doi.org/10.1155/2012/189096
Sagai, M., & Bocci, V. (2011). Mechanisms of Action Involved in Ozone Therapy : Is healing induced via a mild oxidative stress ?, 1–18.
Smith, A. J., Oertle, J., Warren, D., & Prato, D. (2015). Ozone Therapy : A Critical Physiological and Diverse Clinical Evaluation with Regard to Immune Modulation , Anti-Infectious Properties , Anti-Cancer Potential , and Impact on Anti-Oxidant Enzymes, (August), 37–48.
Sunday, S. L. (2004). How Ozone Affects Bacteria , Fungus , Molds And Viruses The Effects of Ozone on Pathogens, (October), 3–5.
Uchakin, P. N., Parish, D. C., Dane, F. C., Uchakina, O. N., Scheetz, A. P., Agarwal, N. K., & Smith, B. E. (2011). Fatigue in Medical Residents Leads to Reactivation of Herpes Virus Latency. Interdisciplinary Perspectives on Infectious Diseases, 2011, 1–7. httpss://doi.org/10.1155/2011/571340
White, P. D. (2007). What Causes Prolonged Fatigue after Infectious Mononucleosis—and Does It Tell Us Anything about Chronic Fatigue Syndrome? The Journal of Infectious Diseases, 196(1), 4–5. httpss://doi.org/10.1086/518615
Contact us with your preferred method. Calls are redirected to Qld Australia.
If we are not answering leave a message so we can call you back.
Sunshine Coast Noosaville Qld 4566 Australia
TOOL FREE CALL
Australia 1 800 719 673
USA & Canada 1 800 810 4796
Calls are redirected to Australia. Please leave a message so we can call you back.
WHATSAPP +61 447 609022
ABN: 32 621 367 557
ACN: 621 367 557
Create your FREE account now!
After you have created an account and signed in, you have un restricted access to all disease protocols and applications.
Ozone therapy is a well researched therapy and very popular in many European countries. Unfortunately Ozone therapy is not FDA and TGA approved and therefore we have to hide relevant content until you have accepted our Disclaimer.
By signing up to the O3academy.com you confirm to have read and accepted our legal disclaimer.